Indications and uses
Use for the treatment of Acne.
Use for the treatment of Acne.
Clean the skin thoroughly before applying this product. Cover the entire affected area with a thin layer one to three times daily. Because excessive drying of the skin may occur, start with one application daily, then gradually increase to two or three times daily if needed or as directed by a doctor. If bothersome dryness or peeling occurs, reduce application to once a day or every other day.
Drug Facts
Salicylic Acid 0.5%
Acne Treatment
For external use only.
Keep out of reach of children.
Water (Aqua), Methyl Perfluorobutyl Ether, Isododecane, Propanediol, Polymethylsilsesquioxane, Niacinamide, Glycerin, Polysilicone-11, Oryza Sativa Bran Extract, Boswellia Serrata Extract, Oligopeptide-10, Phenoxyethanol, Butylene Glycol, PPG-3 Benzyl Ether Myristate, Polysorbate 20, Triethanolamine, Hydroxyethylcellulose, Sodium Polyacrylate, Ethylhexyl Cocoate, Caprylyl Glycol, Decyl Glucoside, Cocamidopropyl Betaine, Hexylene Glycol, Sodium Sulfate, Sodium Benzoate, Honey Extract, Sodium Chloride.
Developed + Dist by
noon
AESTHETICS
TLV, 62153 | Made in Israel
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 78863-3002 | 78863-3002-1, 78863-3002-2 |
Every source-derived ingredient row is available through these pages.
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| ACNO Solution ACNE TREATMENT | SALICYLIC ACID | Noon Aesthetics M.R. Ltd | 4a267e44-03d9-471f-9708-a5c60ff69097 | 2026-07-24 | Warnings | 78863-3002-2 78863-3002-1 78863-3002 78863300201 78863300202 2553df56-d06c-4793-8dc5-3037807b17c2 4a267e44-03d9-471f-9708-a5c60ff69097 |
Adverse event summaries are temporarily unavailable. Other product information remains available.